# Psoriatic Arthritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/psoriatic-arthritis

> 12 upcoming FDA catalysts in psoriatic Arthritis: tulisokibart (MRK) on Feb to May 2027 (topline data readout); tulisokibart (MRK) on February 2027 (primary completion); zasocitinib (TAK) on May to Aug 2027 (topline data readout); zasocitinib (TAK) on May to Aug 2027 (topline data readout); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2027 | [Tulisokibart topline data readout](https://sec-api.dev/pdufa/tulisokibart) | MRK | Psoriatic Arthritis | scheduled | "NCT07486960 (Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486960)) |
| February 2027 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Psoriatic Arthritis | scheduled | "NCT07486960 (Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486960)) |
| May to Aug 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671483)) |
| May to Aug 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671496)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671483)) |
| May 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06671496)) |
| August 2029 | [ABBV-701 primary completion](https://sec-api.dev/pdufa/abbv-701) | ABBV | Psoriatic Arthritis | scheduled | "NCT06865105 (Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865105)) |
| Aug to Nov 2029 | [ABBV-701 topline data readout](https://sec-api.dev/pdufa/abbv-701) | ABBV | Psoriatic Arthritis | scheduled | "NCT06865105 (Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865105)) |
| Dec 2029 to Mar 2030 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07286058 (Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286058)) |
| December 2029 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07286058 (Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286058)) |
| Apr to Jul 2030 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07871721 (A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-04-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871721)) |
| April 2030 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Psoriatic Arthritis | scheduled | "NCT07871721 (A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-04-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871721)) |

## Drugs

- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [ABBV-701](https://sec-api.dev/pdufa/abbv-701) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/psoriatic-arthritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Psoriatic Arthritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/psoriatic-arthritis

```bibtex
@misc{secapidev_indications_psoriatic_arthritis_20261116,
  title        = {Psoriatic Arthritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/psoriatic-arthritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_psoriatic_arthritis_20261116","title":"Psoriatic Arthritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/psoriatic-arthritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
